BMS-599626 (also known as BMS599626, AC480, and CAS: 714971-09-2) is a small molecule inhibitor developed by Bristol-Myers Squibb. It is used in the treatment of cancer and has shown promising results in clinical trials.
Chemical name: The chemical name of BMS-599626 is N-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-4-(4-methylpiperazin-1-yl)benzamide.
Molecular formula: The molecular formula of BMS-599626 is C29H38N4O2.
Formula weight: The formula weight of BMS-599626 is 482.64 g/mol.
CAS No: The CAS number for BMS-599626 is 714971-09-2.
Top ten keywords from Google and synonyms:
Synonyms:
Health benefits of this product: BMS-599626 is a promising cancer drug that has shown potential in clinical trials. It works by inhibiting the activity of protein kinases, which are enzymes that play a role in the growth and spread of cancer cells. By blocking these enzymes, BMS-599626 can slow or even stop the growth of tumors, making it an effective treatment option for many types of cancer.
Potential effects: BMS-599626 has shown promise in preclinical studies and clinical trials for the treatment of various types of cancer, including lung cancer, breast cancer, and melanoma. In one study, BMS-599626 was shown to significantly inhibit the growth of lung cancer cells both in vitro and in vivo. Another study found that BMS-599626 was able to induce cell death in breast cancer cells.
Product mechanism: BMS-599626 works by inhibiting the activity of protein kinases, which are enzymes that play a role in the growth and spread of cancer cells. Specifically, BMS-599626 targets the kinase activity of EGFR (epidermal growth factor receptor), HER2 (human epidermal growth factor receptor 2), and HER4 (human epidermal growth factor receptor 4). By blocking these enzymes, BMS-599626 can slow or even stop the growth of tumors.
Safety: Like all drugs, BMS-599626 has potential side effects. In clinical trials, the most common side effects reported were fatigue, nausea, vomiting, diarrhea, and decreased appetite. However, these side effects were generally mild to moderate in severity, and most patients were able to continue treatment without interruption.
Side effects: While BMS-599626 has been shown to be generally well-tolerated, there are some potential side effects to be aware of. These may include fatigue, nausea, vomiting, diarrhea, decreased appetite, rash, and elevated liver enzymes. Patients should always discuss any concerns they have about potential side effects with their doctor before starting treatment.
Dosing information: The dosing regimen for BMS-599626 varies depending on the type of cancer being treated and other individual factors. It is typically given orally once daily, either alone or in combination with other cancer drugs. Patients should always follow their doctor's instructions regarding dosing and scheduling of BMS-599626.
Conclusion: BMS-599626 is a promising cancer drug that has shown potential in clinical trials. As a small molecule inhibitor, it works by blocking the activity of protein kinases that play a role in the growth and spread of cancer cells. While it does have potential side effects, it has been generally well-tolerated in clinical trials. Overall, BMS-599626 represents an important advancement in the treatment of cancer and offers hope for patients with a variety of different cancer types
